Strontium Ranelate - A Novel Therapy for Osteoporosis or a Permutation of the Same?

New England Journal of Medicine

Volumn 350, Issue 5, 2004, Pages 504-506

  Fuleihan, Ghada El Hajj ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

STRONTIUM;

BONE DENSITY; BONE MINERAL; BONE MINERALIZATION; DOSE RESPONSE; DRUG EFFECT; EDITORIAL; FRACTURE; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL;

ANIMALS; BONE DENSITY; BONE REMODELING; CLINICAL TRIALS; FEMALE; HUMANS; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS, POSTMENOPAUSAL; PLACEBOS; THIOPHENES;

EID: 1642499228     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe038229     Document Type: Editorial

References (15)

1. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68.
2. Boivin G, Deloffre P, Perrat B, et al. Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration. J Bone Miner Res 1996;9:1302-11.
3. Shorr E, Carter AC. The usefulness of strontium as an adjuvant to calcium in the remineralization of the skeleton in man. Bull Hosp Joint Dis 1952;13:59-66.
4. Marie PJ, Ammann P, Boivin G, Rey C. Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 2001; 69:121-9.
5. Marie PJ, Hott M, Modrowski D, et al. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 1993;8:607-15.
6. Hott M, Deloffre P, Tsouderos Y, Marie PJ. S12911-2 reduces bone loss induced by short term immobilization in rats. Bone 2003; 33:115-23.
7. Delannoy P, Bazot D, Marie PJ. Long-term treatment with strontium ranelate increases vertebral bone mass without deleterious effects in mice. Metabolism 2002;51:906-11.
8. Brown EM. Is the calcium receptor a molecular target for the actions of strontium on bone? Osteoporos Int 2003;14:Suppl 3:S25-S34.
9. Reginster JY, Deroisy R, Dougados M, Juspin I, Colette J, Roux C. Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two year, double-masked, dose-ranging, placebo-controlled PREVOS trial. Osteoporos Int 2002;13:925-31.
10. Meunier PJ, Slosman DO, Delmas PD, et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis: a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002;87:2060-6.
11. Reginster J-Y, Sawicki A, Devogelaer JP, et al. Strontium ranelate reduces the risk of hip fractures in women with postmenopausal osteoporosis. Osteoporos Int 2002;13:Suppl 3:814. abstract.
12. World Medical Association clarification of general assembly text. Ferney-Voltaire, France: World Medical Association, 2000. (Accessed January 8, 2004, at http://www.wma.net/e/policy/bB.htm.)
13. Osteoporosis trials: ethical considerations and study design. J Bone Miner Res 2003;18:1101-62.
14. Chesnut CH III, Rosen CJ. Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture. J Bone Miner Res 2001;16:2163-72.
15. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349:1207-15.